NOVATO, Calif., Oct. 17, 2023 (GLOBE NEWSWIRE) — Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultrarare diseases, today announced that it has commenced an underwritten public offering of up to $300,000,000 of shares of its common stock.…Read More
Ultragenyx Pharmaceutical Inc Ultragenyx Announces Proposed Public Offering of Common Stock
